関連する実験動画
Updated: Jan 8, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
Published on: June 26, 2020
グルコース-6-リン酸デヒドロゲナーゼ欠損症はE型肝炎ウイルス(HEV)の侵入を促進し、肝障害を悪化させる
Dongxue Chen1, Xiaoxia Hu1, Yuanwen Xue1
1Medical School, The Academy for Cells and Life Health, Kunming University of Science and Technology, Kunming, PR China.
Background:
Glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PDd) is an common enzyme deficiency disease, inducing hemolysis, hyperbilirubinemia, and jaundice, as well as liver dysfunction, in approximately 400 million patients. Patients with G6PDd are more susceptible to viruses infection than those without. However, the incidence and severity of hepatitis E virus (HEV) infection in patients with G6PDd are largely unknown.
Methods:
The prevalence of HEV in patients with G6PDd was investigated. Susceptibility to HEV was evaluated in a hepatoma cell line with G6PD knockdown, and the interaction between HEV and G6PD was assessed.
Results:
The prevalence of HEV infection was higher in patients with G6PDd (23.8%, 25/105) than in patients with normal G6PD levels (0.65%, 2/307), indicating that patients with G6PDd are susceptible to HEV infection. Higher rates of hyperbilirubinemia (64% vs. 36.25%) and pneumonia (28% vs. 12.5%) were observed in HEV-infected patients with G6PDd than in patients with normal G6PD values. G6PD knockdown facilitated HEV entry and aggravated oxidative stress with the significant inhibition of glutathione to benefit viral replication but was restricted by NADPH reduction. Co-IP and colocation assays revealed that HEV ORF3 interacted with G6PD. HEV infection stimulated the expression of G6PD in a manner dependent on nuclear factor E2-related factor 2 activation. Consequently, severe apoptosis was observed in HEV-infected cells with G6PD knockdown.
Conclusions:
Patients with G6PDd are susceptible to HEV infection. The facilitation of HEV entry and aggravation of oxidative stress may contribute to HEV susceptibility in patients with G6PDd and severe disease.
関連する概念動画
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Energy-requiring Steps of Glycolysis
Other Glycolytic Pathways
Glycolysis: Preparatory Phase

